Cooperative Agreement NU58DP005418

This Cooperative Agreement award for $703,321.00, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research federal grant program (CFDA 93.393), will support the adaptation and implementation of an evidence-based patient navigation intervention for adolescent and young adult (AYA) cancer survivors. The project aims to improve coordination of care, including surveillance for cancer recurrence, management of long-term effects, and delivery of preventive and...

The Defense Health Agency awarded a $3,644,169 Project Grant to the ECOG-ACRIN Medical Research Foundation, Inc. to advance precision and equity in breast cancer care. This funding, provided through the Military Medical Research and Development program (CFDA 12.420), supports a 4-year clinical research extension to the TAILORx study, which aims to improve personalized treatment for breast cancer patients. As a subrecipient, the Foundation has also supported research at Dana-Farber Cancer...

This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will fund a $717,786 study to evaluate the efficacy of a tailored medication adherence-promotion intervention called SUMMIT for adolescents and young adults (AYAs) with cancer. The study aims to improve medication adherence among AYAs, who often struggle with adherence, leading to poor health outcomes like relapse and death. The Children's Hospital Medical Center in...

The National Cancer Institute (NCI) awarded a $4,236,812 Project Grant under the Cancer Cause and Prevention Research federal grant program (CFDA 93.393) to Children's Hospital Los Angeles (CHLA). The grant, effective September 10, 2025 through August 31, 2029, will fund a study to evaluate the use of a patient navigation intervention to improve transition outcomes for young adult survivors of childhood cancer, particularly those from low socioeconomic status and underinsured/uninsured...

This $858,166 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) is for a randomized trial of a targeted palliative care intervention for patients with metastatic breast cancer. The grant supports a 5-year study to be conducted by The General Hospital Corporation (Massachusetts General Hospital) to improve documentation of end-of-life care preferences, delivery of end-of-life care, and patient-reported outcomes for this patient population....

This federal Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research program) provides $651,859 to the Ann & Robert H Lurie Children's Hospital of Chicago to conduct the "#AYAOSM: An Influencer-Driven Social Media Intervention for Oral Chemotherapy Adherence" research project. The 5-year project aims to develop and evaluate a social media-based intervention to improve oral chemotherapy adherence among adolescents and young adults...

This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $197,414 to Rutgers, The State University of New Jersey to conduct research on "Dyadic and Social Network Influences on Health and Well-Being Among Young Adults with Cancer". The award will support the grantee's training goals over a 5-year period from August 7, 2025 to July 31, 2030. Key objectives include enhancing the grantee's expertise in dyadic functioning of young adult...

This federal Project Grant award, with a total funding amount of $882,470, was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Baylor College of Medicine, a prestigious private non-profit health sciences university in Texas. The primary objective of this 5-year award is to expand the awardee's role as a leader in the design and conduct of NCI-funded clinical trials for children, adolescents, and young adults with cancer, particularly hematologic...

This Project Grant award of $109,076 from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to identify patterns of gene deletions in metastatic breast cancer. The award, which runs from January 21, 2026 to July 31, 2029, aims to leverage machine learning techniques and comprehensive autopsy data to create a detailed landscape of genomic evolution in late-stage metastatic disease. The research, conducted by the University of Pittsburgh, seeks to...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $671,757 to Virginia Commonwealth University to conduct the "Supportive Tailored Exercise Program for Survivors of Breast Cancer (STEPS-BC)" study. The objective is to test whether a tailored home-based exercise intervention, delivered in parallel with adjuvant chemotherapy, can preserve exercise capacity, left ventricular function, and health-related quality...